Fasting glucose measurement as a potential first step screening for glucose metabolism abnormalities in women with anovulatory polycystic ovary syndrome

Human Reproduction

Volumn 28, Issue 8, 2013, Pages 2228-2234

  Veltman Verhulst, Susanne M ^a   Goverde, Angelique J ^a   Van Haeften, Timon W ^a   Fauser, Bart C J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

diabetes; fasting; glucose; OGTT; polycystic ovary syndrome

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; RISK FACTOR;

EID: 84880534375     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det226     Document Type: Article

References (42)

1. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 108: polycystic ovary syndrome. Obstet Gynecol 2009; 114:936-949.
2. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 2005; 11:126-134.
3. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35 (Suppl. 1):S11-S63.
4. Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012;27:14-24.
5. Barcellos CR, Rocha MP, Hayashida SA, Nery M, Marcondes JA. Prevalence of abnormalities of glucose metabolism in patients with polycystic ovary syndrome. Arq Bras Endocrinol Metabol 2007;51:601-605.
6. Bhathena RK. Insulin resistance and the long-term consequences of polycystic ovary syndrome. J Obstet Gynaecol 2011;31:105-110.
7. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673-683. (Pubitemid 44605508)
8. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 2006;113:1210-1217. (Pubitemid 44401217)
9. Centraal Bureau voor de Statistiek (CBS). 2010. http://www.cbs.nl/nl-NL/ menu/themas/gezondheid-welzijn/cijfers/default.htm.
10. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785-789. (Pubitemid 30192723)
11. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604. (Pubitemid 23050339)
12. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800. (Pubitemid 28009567)
13. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetesinwomen with polycystic ovary syndrome. Diabetes Care 1999;22:141-146. (Pubitemid 29028311)
14. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN, PCOS/Troglitazone Study Group. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:66-71. (Pubitemid 40116635)
15. Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 2007;50:205-225. (Pubitemid 46279863)
16. Fauser BC, Bouchard P. Uncertainty remains in women with PCOS regarding the increased incidence of cardiovascular disease later in life, despite the indisputable presence of multiple cardiovascular risk factors at a young age. J Clin Endocrinol Metab 2011;96:3675-3677.
17. Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ 2007; 176:933-938. (Pubitemid 46556835)
18. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Br Med J 2007;334:299.
19. Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 2009;24:710-717.
20. Hurd WW, Abdel-Rahman MY, Ismail SA, Abdellah MA, Schmotzer CL, Sood A. Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil Steril 2011;96:1043-1047.
21. Inder WJ. No evidence of benefit for universal screening with 75 g oral glucose tolerance test in polycystic ovary syndrome. Med J Aust 2011; 195:578-579.
22. Ledger WL, Atkin SL, Cho LW. Polycystic ovary syndrome, long-term consequences (green-top 33). Royal College of Obstetricians and Gynaecologists 2007. http://www.rcog.org.uk/womens-health/clinical-guidance/long-term- consequences-polycystic-ovary-syndrome-green-top-33.
23. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169. (Pubitemid 29036695)
24. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90:3236-3242. (Pubitemid 41014281)
25. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25:544-551.
26. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002. (Pubitemid 351656454)
27. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009;15:477-488.
28. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucosetolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16:347-363.
29. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001;16:1995-1998. (Pubitemid 32916235)
30. Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010;42 (Suppl 1):S3-S36.
31. Pesant MH, Baillargeon JP. Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011;95:210-215.
32. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortalityofwomen with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581-586. (Pubitemid 28376967)
33. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-47.
34. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007;88:1389-1395. (Pubitemid 350030974)
35. Stovall DW, Bailey AP, Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt) 2011;20:37-43.
36. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:111-132.
37. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ, Costello MF, Guideline Development Groups. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust 2011;195:S65-S112.
38. Westerveld HE, Hoogendoorn M, de Jong AW, Goverde AJ, Fauser BC, Dallinga-Thie GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol Ther 2008; 119:223-241.
39. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600. (Pubitemid 30337085)
40. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038-2049.
41. World Health Organization (WHO). http://www.who.int/whosis/mort/download/ en/.
42. Yildiz BO, Gedik O. Assessment of glucose intolerance and insulin sensitivity in polycystic ovary syndrome. Reprod Biomed Online 2004;8:649-656. (Pubitemid 38744943)